About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

oh guess what, we have a new patent

http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=DE60119524T&F=0

Nice to see.

Inventor: COTTER TOM (IE); HAYES IAN (IE); MURPHY FINBARR (IE); SEERY LIAM (IE)
Applicant: EIRX THERAPEUTICS LTD (IE)

Genentech bets on small molecules as biogeneric competition looms

28/06/2007 - Genentech has in-licensed two early-stage cancer small molecules developed by Abbott as biogeneric competition is poised to kick off.

Genentech seems to be diversifying its pipeline beyond biologics just at a time where pricing pressure increases and the US government is deciding on clearing a path for the entry of generic versions of biologic drugs on the market.

The biotech giant will work together with Abbott on all aspects of further development and commercialisation of the two drugs, while Abbott will keep their marketing rights outside the US.

Financial terms of the collaboration were not disclosed although some analysts have already estimated the deal as modest.

Genentech said the compounds - ABT-263 and ABT-869 - are targeted therapies that represent promising, unique scientific approaches to treating cancer.

ABT-263, a Bcl-2 family protein antagonist, restores apoptosis - a natural process by which damaged or unwanted cells die and are cleared from the body - in a variety of cancer cells, while ABT-869, a VEGFR-based multi-targeted kinase inhibitor, suppresses tumour growth by preventing the growth of new blood vessels that supply the tumour with oxygen.

Another interesting side of the deal is its early-stage nature - both drugs are in Phase I - which reflects a trend that has been budding over the past year in the biotech industry. After years of biopharma companies showing interest only for late-stage products, it seems that they are shifting their focus to early-stage deals.

According to an Ernst & Young biotech report published recently, this was to some extent because several years of late-stage deal making have left relatively few attractive products in the advanced pipeline that have not already been partnered.

"The trend also reflects that big pharma and big biotechs are eager to energise their pipelines," said the report.

Genentech, the second largest biotech firm in the world with $9.3bn (6.9bn) in sales last year, could have found the right recipe to boost even more its cancer portfolio.


"We believe that these molecules are strong complements to our existing anti- angiogenesis and apoptosis research and development programmes and have the potential to broaden our pipeline with important, innovative compounds," said Hal Barron, senior vice president of Development and chief medical officer for Genentech.

The company who normally specialises in biologics has nevertheless managed to create success with another anti-cancer small molecule: Tarceva (erlotinib hydrochloride).

The biotech firm in-licensed the drug from OSI Pharmaceuticals and brought the drug to the market in 2005.

But Genentech is not the only biotech giant who has been dipping its toe in the small molecule water. Another example of big biotech playing in the big pharma arena is Amgen who recently acquired two small molecule developers in the same week - Alantos for $300m and Ilypsa for $420m.

Meanwhile, the US government is in the process of put in place an approval pathway for generic versions of biologic drugs - a step already taken in Europe where two "biosimilars" are currently marketed.

http://www.biopharma-reporter.com/news/ng.asp?n=77776-genentech-abbott-cancer-biologics


HMMM SOUNDS FAMILIAR

WONDER IF THESE ARE THE MOLECULES OSI RETURNED TO US AND WE HAVE NOW STRUCK A DEAL WITH GENETECH

possible contract soon?????????????????????????????????????????

plm2349
Who knows??????????

I bought a lump of these back in May after reading here up a bit not much, but still more than happy to hold and top up on any weakness.

MGI PHARMA Second Quarter 2007 Financial Results Conference Call to Be Webcast on July 18, 2007


MINNEAPOLIS--(BUSINESS WIRE)--Jul 11, 2007 - MGI PHARMA, INC. (Nasdaq:MOGN) will webcast its second quarter 2007 financial results conference call with investors live over the Internet on Wednesday, July 18, 2007 at 5:00 p.m. Eastern Time. Lonnie Moulder, President and CEO of MGI PHARMA, and members of the Company's executive management team, will review financial results, answer questions from analysts and investors, and provide commentary on MGI PHARMA's business outlook. A press release announcing the Company's financial results for the second quarter 2007 will be issued on Wednesday, July 18, 2007 after the U.S. financial markets close and prior to the start of the webcast.

The live webcast and press release may be accessed by logging on to MGI PHARMA's corporate website at www.mgipharma.com. Please connect to the Company's website at least 15 minutes prior to the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archived version of the webcast will be available through July 25, 2007.

thefordprefect - 11 Jul'07 - 19:58 - 21611 of 21685


BLK just phone MGI and asked about the "zike3" trial.

Sharon, (a pharmacist) didn't sound too sure but said she did not think there were many people enroled on the trial yet. It was in early stages.

I will try one of the others later. they were not available just now .
Cheers, Mike

thefordprefect - 11 Jul'07 - 20:19 - 21612 of 21685


Ok just phoned one of the others - very helpful there is one more slot open in the initial stage, but they will then be shortly opening it up for 10 more patients with either breast and/or coleo-rectal cancer. sending more info by email.
Cheers,
Mike

Mike111D - 11 Jul'07 - 20:26 - 21613 of 21685


Mike, thank you for making the effort to clarify this and for sharing.

thefordprefect - 11 Jul'07 - 21:01 - 21614 of 21685


Sorry, just edited out the contact details as not fair to name the contact
Mike

For Immediate Release 12 July 2007
IDMoS plc
Board Restructuring
IDMoS plc (AIM: IDO) ("IDMoS" or the 'Group'), the specialist in disease detection and monitoring technology, announces that Stephen Westwood, the Group's Chief Executive is leaving the company with immediate effect to pursue other business interests.
John Pool will move from the role of non-Executive Chairman to the position of Interim Executive Chairman.
It is the Board's intention to appoint Graham Lay as Chief Operating Officer of the Group, joining the Board with effect from 17 July 2007. Graham Lay has extensive experience in the medical devices arena, having spent 18 years with Johnson & Johnson, Inc, ultimately achieving the role of Vice President - Worldwide Research and Development, where he was responsible for new product innovation and development, including a significant number of product launches.
He also has substantial experience in the commercialisation of clinical products.
A new Chief Executive will be appointed as soon as practical.
John Pool, Interim Executive Chairman of IDMoS said: "I wish Stephen well in the future. Stephen has been Chief Executive of IDMoS since October 2004, steering the business through its successful flotation on AIM, completing two fundraisings and successfully negotiating a commercialisation agreement with Dentsply.
I am delighted that Graham Lay has agreed to take up the role of Chief Operating Officer. Graham's skills in new product development as well as his strong industry contacts will be invaluable to IDMoS and the Board are confident that this new team will be able to aggressively drive the business forward."
ENDS

hello hello hello.. I think something has leaked ;-)


Breast Cancer : A New Preclinical Research Tool
Main Category: Breast Cancer News
Article Date: 14 Jul 2007 - 0:00 PDT

email to a friend printer friendly view / write opinions rate article newsletters


Latest News For This Category
Further Light Shed On The Mechanisms Regulating ER-Alpha Expression Levels During Breast Cancer
16 Jul 2007
Women With Breast Cancer Carrying BRCA Genetic Mutations Have Similar Survival, Death Rates As Noncarriers, Study Says
16 Jul 2007

At the Institut Curie, Inserm researchers and physicians have established the largest ever panel of human breast cancer xenografts in animal models. Because of their similarity to patient tumors, these models are an exceptional tool for testing the efficacy of new drugs, adapting treatments to tumor characteristics, unraveling resistance to certain treatments, and as a result limiting the need for clinical trials in patients. Institut Curie and Inserm medical oncologists, surgeons, pathologists and biologists collaborated on this work on mouse models which can now be extended to other types of cancers. The 25 breast tumor models are described in a study published in the 1 July 2007 issue of Clinical Cancer Research.

To help clinicians in their search for more effective treatments, Marie-France Poupon and her team in Institut Curie Inserm Unit 612 "Genotoxicology, signaling and experimental radiotherapy" have developed the largest ever series of human breasts cancers grafted into mice. This six-year study would not have been successful without close collaboration between Institut Curie and Inserm medical oncologists, surgeons, pathologists, and biologists.

These breast cancer xenografts in mice reproduce the genetic, genomic, and histological characteristics of the patient-derived tumor tissues. So they recapitulate features of the original tumors, such as overexpression of HER2 receptors, absence or presence of estrogen receptors, mutation of P53, and react identically to chemotherapy.

Twenty-five models of breast tumors in mice of different biological profiles have been established. These models are an excellent preclinical research tool and can be used to test the efficacy of new drugs and novel therapeutic combinations, as well as analyze the response to treatment and adapt it to the tumor characteristics. This will help in the design of clinical trials and hasten the development of new treatments.

This work is continuing within the framework of the creation of a Preclinical Investigation Laboratory in the Translational Research Department at the Institut Curie, with a view to extending this series of tumor models to other types of cancers, such as pediatric cancers, melanoma, lung cancer, ovarian cancer, and cancers of the bronchi, prostate, and colon.

Breast cancer

Breast cancer is the most frequent cancer in women and affects one in ten women in the developed world. Every year in France there are 42 000 new cases. Between 1980 and 2000, the number of cases increased by almost 60%, largely as a result of increasingly efficient detection and because people are living longer. Breast cancer is most commonly detected in women aged between 50 and 69 years of age (half of all cases), but can occur at any age, albeit very rarely before the age of 25. Mortality has declined because of earlier detection and improved treatments combining surgery, radiotherapy, and chemotherapy, depending on the tumor characteristics. When the diagnosis is made early enough, conservative surgery is possible: the tumor is removed and the breast conserved. When the tumor is larger, or is accompanied by extensive precancerous lesions, it is sometimes essential to remove the breast (mastectomy).

INSTITUT CURIE
26, rue d'Ulm
75005 Paris Cedex 05
http://www.curie.fr

EiRx Therapeutics PLC
13 August 2007


For Immediate Release 13 August 2007



EIRX THERAPEUTICS PLC

('EiRx' or 'the Company')

362,000 grant supports cancer drug development programme

New chemistry capability advances EiRx from drug discovery to development, will
drive products towards clinical candidacy


Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company
developing targeted therapies for cancer, is pleased to announce that Enterprise
Ireland has agreed to fund the development of new cancer medicines through a
collaboration with Professor Anita Maguire, Chair of Pharmaceutical Chemistry at
University College Cork ('UCC'), Ireland. The collaboration will establish a
medicinal chemistry team in Cork, under the supervision of Prof Maguire, to
optimise compounds emerging from the Company's EnPADTM drug discovery platform
and advance them towards clinical trials. The tie-up with Professor Maguire, who
is Director of UCC's prestigious Analytical & Biological Chemistry Research
Facility ('ABCRF'), has attracted funding through Enterprise Ireland's
Innovation Partnership scheme. The grant awards a total of 362,600 over two
years for personnel, materials and overhead costs, and will be reinforced by
EiRx with a further 139,000 in cash and dedicated personnel costs.


As a result of the collaboration, EiRx gains access to medicinal chemistry
skills and facilities via employment of two fully-funded postdoctoral chemists
within Professor Maguire's research group at the ABCRF. Professor Maguire will
lead in the scientific management and leadership of the research programme, and
EiRx will contribute a dedicated cancer biologist and management input. The
collaboration will work on optimisation of tumour-selective pro-apoptotic
molecules identified by EiRx's proprietary EnPADTM platform. Any optimised drug
candidates resulting will then be advanced to formal preclinical and clinical
evaluation.


The collaboration is expected to commence within weeks, and will focus on the
most promising examples from EiRx's panel of molecules with proven selective
biological activity against colon and breast cancer cell lines. The partners
will work over a two year period on the optimisation of multiple compound
series, from which preclinical leads will be selected in due course. Novel
intellectual property generated by the collaboration will be jointly held by the
partners. EiRx will assume responsibility for product development beyond the
lead optimisation stage, and will pay success-based development milestones of up
to 3M per new therapeutic candidate, plus royalties on sales, in return for
exclusive, worldwide rights over UCC's stake in jointly held IP.


Dr Colin Telfer, Chief Executive Officer of EiRx, stated: 'Professor Anita
Maguire is a scientist of the highest standing whose scientific input will help
EiRx deliver next-generation cancer therapeutics to the clinic. We have
identified a lack of medicinal chemistry and lead optimisation skills as a
limiting factor on our ability to advance EiRx's drug development programmes,
and it is gratifying to have secured these skills though enlistment of Professor
Maguire's internationally recognised capabilities. Furthermore, we are delighted
that our efforts have secured the financial backing of Enterprise Ireland. We
see this initiative as the foundation stone of our own dedicated chemistry
capability, which we plan to develop from our operational base in Cork, and we
now look forward to optimising our drug candidates in preparation for clinical
evaluation.'

not much change in the sp !Still a long way to go till we see the BIG 1p

Where is PH these days?; gone very quiet! The latest from Eirx is 'not so good/not so bad'


EiRx Therapeutics PLC
08 November 2007
Notice of general meeting
Business update


The Company is today posting to shareholders a notice convening a general
meeting to be held at noon on 5th December 2007 at the offices of Shepherd and
Wedderburn LLP, Condor House, 10 St Paul's Churchyard, London EC4M 8AL, at which
shareholders will be asked to approve a reorganisation of the Company's share
capital including the division of each EiRx Therapeutics plc ordinary share of
0.2p each into one ordinary share of 0.001p and one deferred share of 0.199p and
the division of each unissued EiRx ordinary share of 0.2p into 200 ordinary
shares of 0.001p. Shareholders are also being asked to give the directors
additional authorities to issue shares for cash.

The Company currently generates limited revenue and needs to raise funds to
support its operations. It has been able to postpone a fundraising for longer
than anticipated through careful control of expenditure and greater than
anticipated grant income. The Company is also pleased to announce that it has
secured a bank overdraft facility of 200,000 that has been guaranteed by Peter
Hoskins. As part of these arrangements, a charge has been granted over the EiRx
group's assets. Even with the benefit of that facility, the Company will need
to raise additional funds by the end of January 2008 in order to continue
trading.

The resolutions are being proposed to enable EiRx to raise funds through a
placing of shares, for which it has received indications of interest, which it
is unable to undertake at present because the current market price of the
Company's shares is below their nominal value. Should the placing be
successful, the funds raised will provide working capital to enable the Company
to continue its drug development programme and its business development
activities. In this regard, the Company is pleased to be announcing today an
update of its drug discovery efforts, including details of new patents filed to
protect novel drug candidates discovered using its EnPAD(TM) cellular screening
technology platform.

The general meeting will be preceded by a technical briefing which will commence
at 10:30 a.m.

So, that was the maybe 'not so good'. Perhaps 'not so bad' is:-

Notable achievements in 2006/7 include:

Development of the EnPAD(TM) drug screening technology to enable
identification of compounds that specifically target cell survival
pathways.

Filing of patent applications on first series of potential anti-cancer
compounds identified using EnPAD(TM), which target the b-catenin signalling
pathway to selectively kill colorectal and breast cancer cells in vitro.

Collaborative research agreement with international diagnostics major
bioMerieux SA.

A total of 2.2M raised for research and development by issue of new
shares, comprising three placements of 1.2M, 0.5M and 0.5M on 31st March
2006, 21st September 2006 and 4th January 2007 respectively.

An R&D alliance with the Analytical & Biological Chemistry Research
Facility ('ABCRF') at University College Cork, to apply the medicinal
chemistry expertise of Professor Anita Maguire and her team to the
optimisation of potential new cancer drugs from EiRx's EnPAD(TM) discovery
platform.

A 362,000 grant from Enterprise Ireland's Innovation Partnership
programme, to support the collaborative drug development alliance with
Professor Maguire and the ABCRF.

For further information please see our website at
http://www.eirx.com

EiRx Therapeutics PLC said it has filed two new patent applications to protect novel drug candidates discovered using its EnPAD platform.

'EiRx's EnPAD technology has again uncovered novel and potently active small molecule drug candidates which are specifically targeting signal pathways know to become dysregulated in cancer cells,' Finbarr Murphy, managing director of EiRx's Cork research laboratory, said.

Maybe there is life in the old dog yet!

Out at the moment last week, I may get back in after the fund raising next Jan.

I'm still holding 2m Driver, decided a while ago to hang on 'til the end, or new beginning, whichever it may be!

Perhaps the end of the beginning or more likely the beginning of the end!

Lol!

Where is spud nowadays?

Still Ramping on ADVFN !!

http://www.biotechnologyireland.com/pooled/articles/BF_EVENTART/view.asp?Q=BF_EVENTART_293930

EiRx Therapeutics PLC
05 December 2007



EIRX THERAPEUTICS PLC ('the Company')

Result of general meeting

At the general meeting of the Company held earlier today, all resolutions were
passed.

Application has been made for the re-admission of the Company's ordinary shares
to trading on AIM as Ordinary Shares of 0.001p with trading under the new
designation expected to commence on 6 December 2007.

With effect from re-admission the Company will have 2,975,743,260 Ordinary
Shares of 0.0001p each in issue.